Sarepta Therapeutics reported Wednesday that sales of its Duchenne muscular dystrophy drug have picked up momentum since the FDA's controversial approval of the treatment last year.
Cambridge-based Sarepta (Nasdaq: SRPT) said that the drug, Exondys 51, had generated $35 million in sales in the second quarter of 2017. That easily exceeded the consensus estimate of analysts, which was around $22 million.
Sarepta also raised its guidance for total revenue in 2017, from more than $95 million to between…
Sarepta Therapeutics reported Wednesday that sales of its Duchenne muscular dystrophy drug have picked up momentum since the FDA's controversial approval of the treatment last year.
Cambridge-based Sarepta (Nasdaq: SRPT) said that the drug, Exondys 51, had generated $35 million in sales in the second quarter of 2017. That easily exceeded the consensus estimate of analysts, which was around $22 million.
Sarepta also raised its guidance for total revenue in 2017, from more than $95 million to between…
